natgillin/translations-raw huggingface dataset:
No clinically relevant differences in elvitegravir or cobicistat pharmacokinetics were observed between patients with moderate hepatic impairment and subjects with normal hepatic function. 
Nisu zapažene klinički značajne razlike u farmakokinetici elvitegravira i kobicistata između bolesnika s umjerenim oštećenjem funkcije jetre i ispitanika s normalnom funkcijom jetre.
Polyvinyl alcohol (E1203) Titanium dioxide (E171) Polyethylene glycol (E1521) Talc (E553b) 
Film ovojnica poli(vinilni alkohol) (E1203) titanijev dioksid (E171)
FOOD SUPPLEMENTS Multivitamin supplements 
Multivitaminski dodaci
Norgestimate (0.180/0.215/0.250 mg once daily)/ Ethinyloestradiol (0.025 mg once daily)/ Emtricitabine/Tenofovir alafenamide (200/25 mg once daily)6 
Norgestimat (0,180/0,215/0,250 mg jedanput na dan)/etinilestradiol (0,025 mg jedanput na dan)/ emtricitabin/tenofoviralafenamid (200/25 mg jedanput na dan)6
Based on non-CYP-mediated elimination pathways for lorazepam, no effect on plasma concentrations is expected upon co-administration with Genvoya. 
CYP-om, ne očekuje se učinak na koncentracije u plazmi nakon istodobne primjene s lijekom Genvoya.
(38.9)b N/A 
(38,9)b
The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM). 
Tenofoviralafenamid je pokazao antivirusnu aktivnost u staničnoj kulturi na sve skupine virusa HIV-1 (M,N i O), uključujući podtipove A, B, C, D, E, F i G (vrijednosti EC50 bile su u rasponu od 0,10 do 12,0 nM) i specifičnu aktivnost na sojeve HIV-2 (vrijednosti EC50 bile su u rasponu od 0,91 do 2,63 nM).
Genvoya demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144. 
U usporedbi sa skupinom E/C/F/TDF, lijek Genvoya pokazao je statističku superiornost u postizanju vrijednosti HIV-1 RNK < 50 kopija/ml u 144. tjednu.
How to store Genvoya 
Kako čuvati lijek Genvoya
Caution is warranted and clinical monitoring is recommended during the co-administration. 
U slučaju istodobne primjene preporučuju se mjere opreza i klinički nadzor.
Therefore, therapy with Genvoya should not be initiated during pregnancy, and women who become pregnant during therapy with Genvoya should be switched to an alternative regimen (see sections 4.4 and 4.6). 
Stoga se terapija lijekom Genvoya ne smije započeti tijekom trudnoće, a žene koje zatrudne za vrijeme terapije lijekom Genvoya treba prebaciti na drugi režim (vidjeti dijelove 4.4 i 4.6).
ANTIARRHYTHMICS Digoxin (0.5 mg single dose)/ Cobicistat (150 mg multiple doses) 
Digoksin (jedna doza od 0,5 mg)/
Concentrations of these immunosuppressant agents may be increased when administered with cobicistat. 
Koncentracije ovih imunosupresiva mogu se povećati s istodobnom primjenom kobicistata.
cisapride (used to relieve certain stomach problems) St. John's wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it lovastatin, simvastatin (used to lower blood cholesterol) pimozide, lurasidone (used to treat abnormal thoughts or feelings) sildenafil (when used to treat pulmonary arterial hypertension - a lung disease that makes breathing difficult) orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety) 
• ako uzimate jedan od sljedećih lijekova: alfuzozin (primjenjuje se za liječenje povećane prostate) dabigatran (primjenjuje se za sprječavanje i liječenje krvnih ugrušaka) amiodaron, kinidin (primjenjuju se za ispravljanje nepravilnih otkucaja srca) karbamazepin, fenobarbital, fenitoin (primjenjuju se za sprječavanje napadaja) rifampicin (primjenjuje se za sprječavanje i liječenje tuberkuloze i drugih infekcija) dihidroergotamin, ergometrin, ergotamin (primjenjuju se za liječenje migrene) cisaprid (primjenjuje se za ublažavanje određenih želučanih tegoba) gospina trava (Hypericum perforatum, biljni lijek koji se primjenjuje za depresiju i tjeskobu) ili lijekovi koji je sadrže lovastatin, simvastatin (primjenjuju se za snižavanje kolesterola u krvi) pimozid, lurasidon (primjenjuje se za liječenje abnormalnih misli i osjećaja) sildenafil (kad se primjenjuje za liječenje plućne arterijske hipertenzije - bolest pluća koja otežava disanje) midazolam peroralno primijenjen, triazolam (pomaže Vam da zaspete i/ili za ublažavanje tjeskobe)
• adefovir dipivoxil 
• omaglica • proljev
Co-administration of Genvoya and triazolam is contraindicated (see section 4.3). 
Istodobna primjena lijeka Genvoya i triazolama je kontraindicirana (vidjeti dio 4.3).
Baseline viral load ≤ 100,000 copies/mL > 100,000 copies/mL Baseline CD4+ cell count < 200 cells/mm3 ≥ 200 cells/mm3 
≤ 100 000 kopija/ml > 100 000 kopija/ml
No dose adjustment of buprenorphine/naloxone is required. 
Prilagodba doze buprenorfina/naloksona nije potrebna.
Therefore, therapy with Genvoya should not be initiated during pregnancy, and women who become pregnant during therapy with Genvoya should be switched to an alternative regimen (see sections 4.2 and 4.6). 
Stoga terapija lijekom Genvoya ne smije započeti tijekom trudnoće, a žene koje zatrudne za vrijeme terapije lijekom Genvoya treba prebaciti na drugi režim (vidjeti dijelove 4.2 i 4.6).
Concentrations of clarithromycin and/or cobicistat may be altered with co-administration of Genvoya. 
Koncentracije klaritromicina i/ili kobicistata mogu se izmijeniti s istodobnom primjenom lijeka Genvoya.
Cmax, Cmin1 
Srednja vrijednost postotka promjene AUC, Cmax, Cmin1
Therefore, therapy with Genvoya should not be initiated during pregnancy, and women who become pregnant during therapy with Genvoya should be switched to an alternative regimen (see sections 4.2 and 4.4). 
Stoga terapija lijekom Genvoya ne smije započeti tijekom trudnoće, a žene koje zatrudne za vrijeme terapije lijekom Genvoya treba prebaciti na drugi režim (vidjeti dijelove 4.2 i 4.4).
Due to the presence of cobicistat, co-administration with Genvoya may result in increased plasma concentrations of this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions. 
Zbog prisutnosti kobicistata, istodobna primjena s lijekom Genvoya može za posljedicu imati povećane koncentracije ovog lijeka u plazmi, što je povezano s potencijalno ozbiljnim ili životno opasnim nuspojavama.
No clinically relevant differences in elvitegravir, cobicistat, or tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal disease on chronic haemodialysis as compared to those with normal renal function. 
Nisu opažene klinički važne razlike u farmakokinetici elvitegravira, kobicistata ili tenofoviralafenamida između bolesnika sa završnim stadijem bolesti bubrega na kroničnoj hemodijalizi i onih s normalnom funkcijom bubrega.
It is recommended that digoxin levels be monitored when digoxin is combined with Genvoya. 
Prilikom kombinacije digoksina i lijeka Genvoya preporučuje se nadzor razina digoksina.
Norgestimate (0.180/0.215 mg once daily)/ Ethinyloestradiol (0.025 mg once daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)4 
Norgestimat (0,180/0,215 mg jedanput na dan)/etinilestradiol (0,025 mg jedanput na dan)/ elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)4
Concentrations of pitavastatin may be increased when administered with elvitegravir and cobicistat. 
Koncentracije pitavastatina mogu se povećati s istodobnom primjenom elvitegravira i kobicistata.
Caution should be exercised when co-administering Genvoya with pitavastatin. 
Genvoya i pitavastatina mora se provoditi s oprezom.
Clinical monitoring is recommended upon co-administration of Genvoya. 
Klinički nadzor preporučuje se kod istodobne primjene lijeka Genvoya.
Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinyloestradiol and containing drospirenone or norgestimate as the progestogen or should use an alternative reliable method of contraception (see sections 4.5 and 4.6). 
30 µg etinilestradiola i drospirenon ili norgestimat kao progestagen ili moraju primjenjivati drugu pouzdanu metodu kontracepcije (vidjeti dijelove 4.5 i 4.6).
The mean change from baseline in CD4+ cell count and percentage at Week 48 was -43 cells/mm3 and -0.1%, respectively. 
Srednja vrijednost promjene od početnog broja i postotka CD4+ stanica u 48. tjednu bila je -43 stanica/mm3 odnosno -0,1%.
Concentrations of these antiarrhythmic drugs may be increased when co-administered with cobicistat. 
Koncentracije tih antiaritmika mogu se povećati s istodobnomprimjenom kobicistata.
Co-administration with Genvoya may result in increased plasma concentrations of salmeterol, which is associated with the potential for serious or life-threatening adverse reactions. 
Istodobna primjena lijeka Genvoya može za posljedicu imati povećane koncentracije salmeterola u plazmi, što je povezano s potencijalno ozbiljnim ili životno opasnim nuspojavama.
In virologically suppressed patients 
U bolesnika kod kojih je virus suprimiran
Cockcroft-Gault method, and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF (see also section 4.4). 
U ispitivanjima u bolesnika koji prethodno nisu bili liječeni, lijek Genvoya bio je povezan s manjim utjecajem na parametre sigurnosti primjene za bubrege (mjereno nakon 144 tjedna liječenja prema procijenjenoj brzini glomerularne filtracije Cockcroft-Gaultovom metodom i omjerom proteina i kreatinina u mokraći, te nakon 96 tjedana liječenja omjerom albumina i kreatinina u mokraći) u usporedbi s E/C/F/TDF (vidjeti također dio 4.4).
The mean baseline CD4+ cell count was 636 cells/mm3 (range 263-1,498). 
Srednja vrijednost početnog broja stanica CD4+ bio je 636 stanica/mm3 (u rasponu od 263 do 1498).
HIV-1 RNA ≥ 50 copies/mLd 
HIV-1 RNK < 50 kopija/ml
AUC: ↑ 525% Cmin: ↑ 394% Cmax: ↑ 384% 
25-O-dezacetilrifabutin AUC: ↑ 525% Cmin: ↑ 394% Cmax: ↑ 384%
{MM/YYYY} 
SN: {broj}
Concentrations of antidepressant agents may be increased when co-administered with cobicistat. 
Koncentracije antidepresiva mogu se povećati pri istodobnoj primjeni s kobicistatom.
Concentrations of sertraline are not affected upon co-administration with Genvoya. 
Istodobna primjena s lijekom Genvoya ne utječe na koncentracije sertralina.
AUC: ↔ Cmin: ↓ 66% Cmax: ↔ 
Kobicistat: AUC: ↔ Cmin: ↓ 66% Cmax: ↔
Genvoya [Outer packaging only] 
16. PODACI NA BRAILLEOVOM PISMU Genvoya [samo vanjsko pakiranje]
Concentrations of atorvastatin are increased when co-administered with elvitegravir and cobicistat. 
Koncentracije atorvastatina povećane su kada se primjenjuje s elvitegravirom i kobicistatom.
Three patients with emergent HIV-1 resistance to Genvoya were identified (M184M/I; M184I+E92G; M184V+E92Q) up to Week 96 in a clinical study of virologically suppressed patients who switched from a regimen containing emtricitabine/tenofovir disoproxil and a third agent (GS-US-292-0109, n = 959). 
U kliničkom ispitivanju u bolesnika kod kojih je virus suprimiran te koji su prešli s režima koji sadrži emtricitabin/tenofovirdizoproksil i treći lijek (GS-US-292-0109, n = 959), do 96. tjedna identificirana su tri bolesnika s novonastalom rezistencijom HIV-1 (M184M/I; M184I+E92G; M184V+E92Q) na lijek Genvoya.
Concentrations of telithromycin and/or cobicistat may be altered with co-administration of Genvoya. 
Koncentracije telitromicina i/ili kobicistata mogu se izmijeniti s istodobnom primjenom lijeka Genvoya.
Missing data during window but on study drug Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by subgroup 
Udio (%) bolesnika s HIV-1 RNK < 50 kopija/ml po podskupinama Dob
Concurrent administration of salmeterol and Genvoya is not recommended. 
Ne preporučuje se istodobna primjena salmeterola i lijeka
Concentrations of rosuvastatin are transiently increased when administered with elvitegravir and cobicistat. 
Koncentracije rosuvastatina kratkotrajno su povećane kada se primjenjuje s elvitegravirom i kobicistatom.
Buprenorphine: AUC: ↑ 35% Cmin: ↑ 66% Cmax: ↑ 12% 
AUC: ↑ 35% Cmin: ↑ 66% Cmax: ↑ 12%
Careful patient monitoring and dose adjustment of metformin is recommended in patients who are taking Genvoya. 
U bolesnika koji uzimaju lijek Genvoya preporučuju se poman nadzor i prilagodba doze metformina.
 Tell your doctor if you are taking these or any other medicines. 
kolhicin  Obavijestite svog liječnika ako uzimate navedene ili bilo koje druge lijekove.
AUC: ↓ 21% Cmin: ↓ 67% Cmax: ↔ 
Elvitegravir: AUC: ↓ 21% Cmin: ↓ 67% Cmax: ↔
Elvitegravir: AUC: ↑ 48% Cmin: ↑ 67% 
Elvitegravir: AUC: ↑ 48% Cmin: ↑ 67% Cmax: ↔
In Study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of Genvoya were evaluated in an open-label study in HIV-1 infected, treatment-naïve adolescents between the ages of 12 to < 18 years, weighing ≥ 35 kg (n = 50) in Cohort 1, and in virologically suppressed children between the ages of 8 to < 12 years, weighing > 25 kg (n = 23) in Cohort 2. 
U otvorenom ispitivanju GS-US-292-0106 u adolescenata u dobi od 12 do < 18 godina s tjelesnom težinom ≥ 35 kg (n = 50) zaraženih virusom HIV-1 koji prethodno nisu bili liječeni u kohorti 1 i u djece u dobi od 8 do < 12 godina s tjelesnom težinom > 25 kg (n = 23) s virološkom supresijom u kohorti 2 procijenjene su djelotvornost, sigurnost i farmakokinetika lijeka Genvoya.
NARCOTIC ANALGESICS Methadone (80-120 mg)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily) 
Metadon (80-120 mg)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)
Co-administration with dabigatran etexilate, a P-glycoprotein (P-gp) substrate, is contraindicated (see section 4.5). 
Istodobna primjena s dabigatraneteksilatom, supstratom P-glikoproteina (P-gp) je kontraindicirana
TAFb TFVb EVGe COBIe FTCe TAFf 
EVGe COBIe FTCe
Tenofovir alafenamide 
Tenofoviralafenamid
Each Genvoya film-coated tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide. 
Jedna filmom obložena tableta lijeka Genvoya sadrži 150 mg elvitegravira, 150 mg kobicistata, 200 mg emtricitabina i tenofoviralafenamidfumarata što odgovara 10 mg tenofoviralafenamida.
ORAL CONTRACEPTIVES Drospirenone/Ethinyloestradiol (3 mg/0.02 mg single dose)/ Cobicistat (150 mg once daily) 
Drospirenon/etinilestradiol (jedna doza od 3 mg/0,02 mg)/ kobicistat
No dose adjustment of ledipasvir/sofosbuvir and Genvoya is warranted upon co-administration. 
Nije potrebna prilagodba doze kod istodobne primjene ledipasvira/sofosbuvira i lijeka Genvoya.
The mean change from baseline in CD4+ cell count at Week 48 was -2 cells/mm3. 
Srednja vrijednost promjene od početne vrijednosti u broju stanica CD4+ u 48. tjednu bila je 2 stanice/ mm3.
Seventy-nine percent were male, 63% were White, 18% were 
Sedamdeset i devet posto su bili muškarci, 63% su bili bijelci, 18% crnci i 14% azijati.
Each film-coated tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide. 
Jedna filmom obložena tableta sadržava 150 mg elvitegravira, 150 mg kobicistata, 200 mg emtricitabina i tenofoviralafenamidfumarata što odgovara 10 mg tenofoviralafenamida.
Telithromycin 
Telitromicin
Anti-hepatitis C virus medicinal products Ledipasvir (90 mg once daily)/ Sofosbuvir (400 mg once daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)/ Emtricitabine (200 mg once daily)/ Tenofovir alafenamide (10 mg once daily)5 
Lijekovi protiv virusa hepatitisa C Ledipasvir (90 mg jedanput na dan)/sofosbuvir (400 mg jedanput na dan)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)/emtricitabin (200 mg jedanput na dan)/ tenofoviralafenamid (10 mg jedanput na dan)5
In vitro studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes. 
A u PBMC-ovima (uključujuću limfocite i druge ciljne stanice HIV-a) i makrofazima te pomoću karboksilesteraze-1 u hepatocitima.
Antimycobacterials Rifabutin (150 mg every other day)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily) 
Rifabutin (150 mg svaki drugi dan)/ elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)
Co-administration with Genvoya may result in increased plasma concentrations of this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions. 
Istodobna primjena lijeka Genvoya može za posljedicu imati povećane koncentracije ovog lijeka u plazmi, što je povezano s potencijalno ozbiljnim ili životno opasnim nuspojavama.
Caution should be exercised, including consideration of dose reduction, when co-administering Genvoya with tadalafil for the treatment of pulmonary arterial hypertension. 
Istodobnu primjenu lijeka Genvoya i tadalafila za liječenje plućne arterijske hipertenzije treba provoditi s oprezom, uključujući i razmatranje snižavanja doze.
AUC: ↓ 25% Cmin: ↓ 44% Cmax: ↔ 
Etinilestradiol: AUC: ↓ 25% Cmin: ↓ 44% Cmax: ↔
Therapeutic monitoring is recommended upon co-administration with Genvoya. 
Terapijski nadzor se preporučuje prilikom istodobne primjene s lijekom Genvoya.
HIV-1 RNA < 20 copies/mL Treatment difference 
HIV-1 RNK < 20 kopija/ml
HIV-1 infected patients with mild to moderate renal impairment In Study GS-US-292-0112, the efficacy and safety of Genvoya were evaluated in an open-label clinical study of 242 HIV-1 infected patients with mild to moderate renal impairment (eGFRCG: 30-69 mL/min). 
U otvorenom kliničkom ispitivanju GS-US-292-0112 na 242 bolesnika zaražena virusom HIV-1 s blagim do umjerenim oštećenjem funkcije bubrega (eGFRCG: 30-69 ml/min) procijenjena je djelotvornost i sigurnost lijeka Genvoya.
Co-administration of Genvoya and orally administered midazolam is contraindicated (see section 4.3). 
Istodobna primjena lijeka Genvoya i midazolama primijenjenog peroralno je kontraindicirana (vidjeti dio 4.3).
ANTICONVULSANTS Carbamazepine (200 mg twice daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily) 
Karbamazepin (200 mg dvaput na dan)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)
(may affect more than 1 in 10 people) • feeling sick (nausea) 
(mogu se javiti u više od 1 na 10 osoba)
4.1% (95% CI: 1.6% to 6.7%, p < 0.001c) 
4,1% (95% CI: 1,6% do 6,7%,
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mLf 
Prekid primanja ispitivanog lijeka zbog nuspojava ili smrtie Prekid primanja ispitivanog lijeka iz drugih razloga i posljednje dostupne vrijednosti HIV-1 RNK
 If any of the side effects get serious tell your doctor. 
Ako se neka od ovih nuspojava pogorša, obavijestite svog liječnika.
Sofosbuvir (400 mg once daily)/ Velpatasvir (100 mg once daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)/ Emtricitabine (200 mg once daily)/ Tenofovir alafenamide (10 mg once daily)5 
Sofosbuvir (400 mg jedanput na dan)/velpatasvir (100 mg jedanput na dan)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)/emtricitabin (200 mg jedanput na dan)/ tenofoviralafenamid (10 mg jedanput na dan)5
Sofosbuvir: 
Sofosbuvir/velpatasvir/
In a pooled analysis, genotyping was performed on plasma HIV-1 isolates from antiretroviral-naïve patients receiving Genvoya in Phase 3 studies GS-US-292-0104 and GS-US-292-0111 with HIV-1 RNA ≥ 400 copies/mL at confirmed virologic failure, Week 144, or time of early study drug discontinuation. 
GS-US-292-0111, s HIV-1 RNK ≥ 400 kopija/ml pri potvrđenom virološkom neuspjehu, u 144. tjednu ili u vrijeme ranog prekida primanja ispitivanog lijeka te je provedena analiza objedinjenih podataka.
No dose adjustment of sofosbuvir/velpatasvir/voxilaprevir and Genvoya is warranted upon co-administration. 
Nije potrebna prilagodba doze kod istodobne primjene sofosbuvira/velpatasvira/voksilapr evira i lijeka Genvoya.
Tacrolimus 
salmeterol
No dose adjustment of sofosbuvir/velpatasvir and Genvoya is warranted upon co-administration. 
Nije potrebna prilagodba doze kod istodobne primjene sofosbuvira/velpatasvira i lijeka Genvoya.
Clinical monitoring of therapeutic effects and adverse reactions is recommended when these medicinal products are concomitantly administered with Genvoya. 
U slučaju primjene lijeka Genvoya i ovih lijekova u isto vrijeme preporučuje se klinički nadzor terapijskih učinaka i nuspojava.
In Study GS-US-292-1515, the efficacy and safety of Genvoya were evaluated in an open-label study in HIV-1 infected, virologically suppressed adolescents between the ages of 12 and 18 years, weighing ≥ 35 kg (n = 50). 
U otvorenom ispitivanju GS-US-292-1515 u adolescenata u dobi od 12 do 18 godina s tjelesnom težinom ≥ 35 kg (n = 50) zaraženih virusom HIV-1 koji su imali virološku supresiju procijenjene su djelotvornost i sigurnost lijeka Genvoya.
• medicines used to treat pulmonary arterial hypertension: 
• lijekove koji se primjenjuju za liječenje plućne arterijske hipertenzije: bosentan i tadalafil
Clinical monitoring should be made upon co-administration with Genvoya. 
Klinički nadzor mora se primijeniti kod istodobne primjene lijeka Genvoya.
Tenofovir alafenamide: 
Tenofoviralafenamid:
Missing data during window but on study drug Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by prior treatment regimen EFV/FTC/tenofovir disoproxil 
Udio (%) bolesnika s HIV-1 RNK < 50 kopija/ml na prvotnom režimu liječenja
AUC: ↔ Cmin: ↑ 46% Cmax: ↔ 
Velpatasvir: AUC: ↔ Cmin: ↑ 46% Cmax: ↔
At Week 144, 83.1% (197/237 patients) maintained HIV-1 RNA < 50 copies/mL after switching to Genvoya. 
Nakon prebacivanja na lijek Genvoya, 83,1% (197/237 bolesnika) bolesnika je u 144. tjednu zadržalo HIV-1 RNK < 50 kopija/ml.
AUC: ↑ 43% Cmin: ↑ 51% Cmax: ↑ 40% 
Karbamazepin: AUC: ↑ 43% Cmin: ↑ 51% Cmax: ↑ 40%
Amlodipine Diltiazem Felodipine Nicardipine Nifedipine Verapamil 
Felodipin Nikardipin Nifedipin
At baseline, median CD4+ cell count was 742 cells/mm3 (range: 255 to 1,246) and median CD4+% was 34% (range: 21 to 53%). 
255 - 1246) a medijan CD4+% bio je 34% (raspon: 21 - 53%).
Cmax: ↑ 41% 
AUC: ↔ Cmax: ↑ 41%
You must remain under the care of your doctor while taking Genvoya. 
Za vrijeme uzimanja lijeka Genvoya morate ostati pod nadzorom svog liječnika.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM. Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM). 
Antivirusno djelovanje elvitegravira na laboratorijske i kliničke izolate virusa HIV-1 procijenjeno je na limfoblastoidnim stanicama, monocitnim/makrofagnim stanicama i limfocitima periferne krvi, te su vrijednosti 50%-tne učinkovite koncentracije (EC50) bile u rasponu od 0,02 do 1,7 nM.
Sirolimus 
Sirolimus Takrolimus
Emtricitabine: 
Buprenorfin:
Atorvastatin (10 mg single dose)/Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)/Emtricitabine (200 mg once daily)/Tenofovir alafenamide (10 mg once daily) 
Atorvastatin (jedna doza od 10 mg)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)/emtricitabin (200 mg jedanput na dan)/tenofoviralafenamid (10 mg jedanput na dan)
Apixaban Rivaroxaban Edoxaban 
• mučnina Česte nuspojave
Package leaflet: Information for the user Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets 
Uputa o lijeku: Informacije za bolesnika Genvoya 150 mg/150 mg/200 mg/10 mg filmom obložene tablete elvitegravir/kobicistat/emtricitabin/tenofoviralafenamid